Doxorubicin is a novel multi-targeted anti-tumor drug with dual anti-tumor effects, inhibiting tumor growth directly by inhibiting RAF/MEK/ERK signaling pathway on the one hand, and blocking tumor neovascularization by inhibiting VEGF and platelet-derived growth factor (PDGF) receptor on the other hand, indirectly inhibiting tumor cell growth. On December 20, 2005, Doxorubicin was approved by the FDA as a first-line treatment for advanced renal cell carcinoma, which is the first drug approved by the FDA for the treatment of renal cancer in 10 years. On June 13, 2006, Doxorubicin was approved by the FDA for the treatment of metastatic liver cancer, and the phase 3 clinical trial of Doxorubicin for the treatment of liver cancer has been completed and is in progress. In addition, preliminary results from clinical studies indicate that sorafenib has potential antitumor effects in solid tumors such as melanoma and non-small cell lung cancer, and clinical trials are ongoing for its use in metastatic melanoma, skin cancer and non-small cell lung cancer. The most common adverse reactions to sorafenib include hand-foot syndrome, fatigue, diarrhea, rash, hypertension, hair loss, pruritus, and nausea and loss of appetite.